Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole- of clinical importance

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1059-1066

  Geisler, J ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

anastrozole; aromatase inhibitors; breast cancer; exemestane; letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; PYRIDOGLUTETHIMIDE; RALOXIFENE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOCHROME P-450 CYP2D6; FEMALE; MICE; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 79953187289     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.58     Document Type: Review

References (52)

1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359: 2131-2139 (Pubitemid 34694019)
2. Bhatnagar AS, Brodie AMH, Long BJ, Evans DB, Miller WR (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76: 199-202 (Pubitemid 32510682)
3. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O (2005) Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 11: 884s-888s (Pubitemid 40111101)
4. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM, (Arimidex, Tamoxifen, Alone or in Combination Trialists' Group) (2006) Comprehensive side effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7: 633-643
5. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole vs tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative 'Arimidex' compared to tamoxifen (PROACT) trial. Cancer 106: 2095-2103 (Pubitemid 43673229)
6. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492
7. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM, Intergroup Exemestane Study (2007) Survival and safety of exemestane vs tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559-570. Erratum in: Lancet 2007; 369: 906
8. Dehal SS, Kupfer D (1997) CYP2D6 Catalyzes Tamoxifen 4-Hydroxylation in Human Liver. Cancer Res 57: 3402-3406 (Pubitemid 27355484)
9. Dezentjé VO, Guchelaar H-J, Nortier JWR, Van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer. Clin Cancer Res 15(1): 15-21
10. Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonhard RCF (1999) Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endoc Rel Cancer 6: 227-230 (Pubitemid 29260056)
11. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26: 1671-1676
12. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511-1515 (Pubitemid 26028086)
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717
14. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12: 1527-1532 (Pubitemid 34065880)
15. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816 (Pubitemid 32880059)
16. Flageng MH, Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 101: 1253-1260
17. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M, Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53
18. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein Lønning P (2001) Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 7: 1230-1236 (Pubitemid 32708674)
19. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751-757 (Pubitemid 34111382)
20. Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbo Y, Aas T, Lonning PE (2008) Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 14: 6330-6335
21. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, Dowsett M (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089-2093 (Pubitemid 28415652)
22. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE (1996) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286-1291 (Pubitemid 26360121)
23. Geisler J, Suzuki T, Helle H, Miki Y, Nagasaki S, Duong NK, Ekse D, Aas T, Evans DB, Lonning PE, Sasano H (2010) Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status. J Steroid Biochem Mol Biol 118: 237-241
24. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventur A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M (1998) Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9: 639-645 (Pubitemid 28318197)
25. Giobbie-Hurder A, Price KN, Gelber RD, International Breast Cancer Study Group; BIG 1-98Collaborative Group (2009) Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 6: 272-287
26. Houghton J (2006) Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group. ESMO Meeting Abstract 243PD
27. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I, Locker GY, Tobias JS, ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62
28. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole vs letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-5546
29. Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ (1992) The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28A: 1712-1716
30. Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5: 207-213 (Pubitemid 38402112)
31. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A (2009) Trastuzumab plus anastrozole vs anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529-5537
32. Lønning PE, Geisler J (2008) Indications and limitations of third-generation aromatase inhibitors. Expert Opin Investig Drugs 17(5): 723-739 (Pubitemid 351843616)
33. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M (1991) The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 63: 789-793
34. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M (1992) The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66: 692-697
35. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, Wilson CR, Angerson WJ, Doughty JC (2009) Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 117: 91-98
36. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, on behalf of BIG 1-98 Collaborative Group and International Breast Cancer Study Group (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18: 859-867 (Pubitemid 47054082)
37. McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacody-namics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy post-menopausal women. J Clin Oncol 24(18S): 16s (Abstract 555)
38. Miller WR (1999) Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast. Endocr Relat Cancer 6: 187-195 (Pubitemid 29260051)
39. Miller WR, Dixon JM, Cameron DA, Anderson TJ (2001) Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 79: 103-107 (Pubitemid 34158784)
40. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole vs tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606 (Pubitemid 32451796)
41. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361: 766-776
42. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643
43. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
44. O'Shaughnessy J (2007) A decade of letrozole: FACE. Breast Cancer Res Treat 105: 67-74 (Pubitemid 47524803)
45. Robertson FR, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, MacPherson E, Lindemann J, Ellis MJ (2009) Activity of fulvestrant 500mg vs anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27(27): 4530-4535
46. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence Jr J, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1): S61-S73 (Pubitemid 41395414)
47. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746 (Pubitemid 26329660)
48. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgran SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13): 1429-1436
49. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastro-zole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multi-center double-blind randomized trial. J Clin Oncol 23: 5108-5116
50. Thürlimann B, for the BIG 1-98 Collaborative & International Breast Cancer Study Groups (2009) Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer update of the BIG 1-98 Primary Core Analysis (PCA). St Gallen Meeting Abstract (Abstract 0161)
51. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A, Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353: 2747-2757
52. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prev Res 3(6): 696-706